Author:
Yao Difei,Shen Hong,Huang Jianjin,Yuan Ying,Dai Haibin
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference20 articles.
1. Cancer statistics in China, 2015;Chen;CA Cancer J Clin,2016
2. [Analysis of pathological types and clinical epidemiology of 6,058 patients with lung cancer];Zhang;Zhongguo Fei Ai Za Zhi,2016
3. [Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients];Wang;Zhongguo Fei Ai Za Zhi,2005
4. Long-term results of a randomized, double-blind, and placebo-controlled phase III trial: Endostar (rh-endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non-small cell lung cancer;Sun;Thorac Cancer,2013
5. Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer;Rong;World J Surg Oncol,2012
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献